Zenvia Phase III PBA Trial Completes Patient Enrollment

AVANIR Pharmaceuticals (NASDAQ: AVNR) announced that it has completed targeted enrollment of patients into the STAR trial, a confirmatory Phase III trial of Zenvia? (dextromethorphan / quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA). The randomized, multi-center, international STAR trial is designed to compare the effects of Zenvia 30/10 mg, Zenvia 20/10 mg and placebo on involuntary crying/laughing episodes rates.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.